Pfizer drug fails in two Phase III lung cancer studies
This article was originally published in Scrip
Executive Summary
Pfizer said its experimental drug dacomitinib failed in two Phase III studies of patients with advanced lung cancer.
You may also be interested in...
Other ASCO 2018 Highlights – It’s Not All IO
The ASCO annual meeting will stage an upset in the EGFR field in lung cancer, and competition in breast cancer within the CDK4/6 and PI3 kinase inhibitor classes will get tighter. Loxo could once again steal the show with a tissue-agnostic drug, this time targeting RET.
Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Bresch is looking to do a sizable deal
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.